Cancer Treatment Advances: Living with Cancer Now Possible for Many | German Cancer Congress 2024
- The landscape of cancer treatment is undergoing a significant shift, moving towards more effective and tailored approaches.
- Specialists are emphasizing the growing ability to treat cancer with increasing precision.
- With CAR T-cell therapy, the body's own immune cells are reprogrammed so that they can recognize and kill cancer cells.
The landscape of cancer treatment is undergoing a significant shift, moving towards more effective and tailored approaches. While a universal cure remains elusive, advancements are increasingly allowing individuals to live longer, healthier lives even with a cancer diagnosis, sometimes managing the disease as a chronic condition. This positive trend is being highlighted at the to , 2026, German Cancer Congress (Deutscher Krebskongress – DKK) in Berlin, the largest and oldest congress of its kind in the German-speaking world.
Precision and Tailored Therapies Drive Progress
Specialists are emphasizing the growing ability to treat cancer with increasing precision. This involves not only refining traditional methods but also incorporating innovative therapies like immunotherapy and cellular cancer treatments. Immunotherapy works by harnessing the body’s own immune system to fight cancer, while cellular therapies, such as CAR T-cell therapy, involve reprogramming immune cells to specifically target and destroy cancer cells.
With CAR T-cell therapy, the body’s own immune cells are reprogrammed so that they can recognize and kill cancer cells. The immune cells are called T cells. They are normally responsible for destroying diseased cells in the body.
Krebsinformationsdienst
Significant successes have been observed with CAR T-cell therapy in treating certain types of leukemia and lymphoma, with some patients experiencing long-term suppression of the disease. Immunotherapy is also demonstrating promise in extending survival and improving prognoses for cancers like lung cancer and melanoma, even in cases where the cancer has metastasized.
mRNA Cancer Vaccines: A Promising Future, Still in Development
Research into mRNA cancer vaccines, building on the technology used in recent viral vaccines, is another area of intense focus. The goal is to train the immune system to recognize and attack cancer cells based on their unique characteristics. However, these vaccines are still under development and are not yet available for clinical use. The journey from initial therapy idea to approved drug can be lengthy, often taking .
The MRNA vaccination became known through the corona vaccination. The technology is also being intensively researched for cancer therapy. The aim is to teach the body’s own immune system to recognize tumor cells based on certain characteristics and to fight them.
Krebsinformationsdienst
Challenges Remain, Particularly with Difficult-to-Treat Cancers
Despite the advancements, significant challenges persist. Progress has been slower in treating cancers like pancreatic cancer and rare cancer types. The complexity of cancer biology and the heterogeneity of tumors contribute to these difficulties. The German Cancer Congress serves as a crucial platform for experts to share research findings and collaborate on strategies to overcome these obstacles.
The congress, led by President Prof. Dr. Anke Reinacher-Schick, Head of the Department of Hematology and Oncology with Palliative Care at St. Josef Hospital of the Catholic Hospital Bochum, University Hospital of the Ruhr University Bochum and Chief of Oncology and Oncological Palliative Care at the DGD Lung Hospital Hemer, will focus on translating cutting-edge research into tangible benefits for patients. The event is organized by the Deutsche Krebsgesellschaft (German Cancer Society) and the Stiftung Deutsche Krebshilfe (German Cancer Aid).
Cancer Incidence in Germany
According to estimates from the Center for Cancer Registry Data (ZfKD), approximately new cancer cases were diagnosed in Germany in , with around cases in men and in women. The most commonly diagnosed cancers were prostate cancer ( cases), breast cancer ( cases), lung cancer ( cases), and colorectal cancer ( cases).
The congress will feature the presentation of new research, with the Congress Presidium calling for abstracts in categories. For the first time, a dedicated submission channel will be available for “The special case” – case studies offering unique insights into challenging clinical scenarios. The submission period begins on and closes on .
The ongoing research and collaborative efforts highlighted at the German Cancer Congress underscore the commitment to improving cancer treatment and outcomes, offering hope for a future where cancer is increasingly manageable and curable.